Literature DB >> 17363794

Fracture risk is a class effect of glitazones.

Robert Short.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17363794      PMCID： PMC1828349          DOI： 10.1136/bmj.39154.373889.DB

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  Drug-induced osteoporosis: beyond glucocorticoids.

Authors:  Karine Briot; Christian Roux
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

2.  The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study.

Authors:  F-Y Hsiao; C D Mullins
Journal:  Diabetologia       Date:  2009-11-27       Impact factor: 10.122

Review 3.  Risk of fractures with glitazones: a critical review of the evidence to date.

Authors:  Michael Bodmer; Christian Meier; Marius E Kraenzlin; Christoph R Meier
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Diabetes, fracture, and bone fragility.

Authors:  Ann V Schwartz; Deborah E Sellmeyer
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

Review 5.  Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Authors:  John Dormandy; Mondira Bhattacharya; Anne-Ruth van Troostenburg de Bruyn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.